Table 7. Risk Estimates of CART Terminal Nodes.
| Nodes | Genotypes | Case ratea (%) | p-value | ORb |
| 1 | ESR1IVS1397W+ADRB3W+ABCG8W+ADRA2A W | 17.2 | − | Reference |
| 2 | ESR1IVS1-397V+SLCO1B1 463 W+ESR2 1082W+ ESR1IVS1-351V +ESRHinf1 W | 21.7 | 0.352 | 0.429 (0.07–2.55) |
| 2 | ESR1IVS1-397W+ ADRB3W+ABCG8W +ADRA2AV+ESR2Bsa1 V | 29.3 | 0.475 | 1.576 (.453–5.479) |
| 3 | ESR1IVS1-397W+ ADRB3W+ABCG8W +ADRA2AV+ESR2Bsa1W | 47.2 | 0.018 | 4.33 (1.29–14.59) |
| 4 | ESR1IVS1-397V+SLCO1B1463 W+ESR21082W+ESR1IVS1-351V +ESRHinf1 V | 56.2 | 0.014 | 5.083 (1.39–18.48) |
| 5 | ESR1IVS1397V+ABCG8V+ESR21082W+ESR1IVS1-351V+ADRB3V | 63.0 | 0.003 | 6.48 (1.90–22.08) |
| 6 | ESR1IVS1-397V+ ADRB3V | 76.9 | 0.002 | 10.05 (2.33–43.29) |
| 7 | ESR1IVS1-397W+ADRB3V+ ESRHinf1W | 78.6 | 0.002 | 24.554 (3.24–185.84) |
W = wild genotype. V = variant genotype.
a
Case rate is the percentage of gallstone patients among all individuals in each node.
b
ORs of terminal nodes were calculated by LR analysis adjusted for age and gender.
Significant values are in bold.